Literature DB >> 6531660

Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.

J Naesdal, G Bodemar, A Walan.   

Abstract

Intragastric pH was measured during physiological conditions over 24-h periods in patients with peptic ulcer disease. After single oral doses of 20, 40, and 80 mg omeprazole we found a dose-dependent reduction in mean intragastric acidity ranging from 38% to 99%. After treatment for 1 week with omeprazole, 40 mg daily, with or without an initial loading dose of 80 mg, intragastric acidity was decreased by more than 99%. This is a more pronounced decrease in acidity than can be achieved even with very high doses of histamine H2-receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6531660

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  19 in total

1.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

3.  Inhibition of gastric secretion following single morning or twice daily oral administration of sufotidine to volunteers.

Authors:  D A Johnston; K G Wormsley
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

4.  Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.

Authors:  D B Jones; C W Howden; D W Burget; G D Kerr; R H Hunt
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

5.  Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.

Authors:  K D Bardhan; J Naesdal; G Bianchi Porro; M Petrillo; M Lazzaroni; R F Hinchliffe; M Thompson; P Morris; M J Daly; N J Carroll
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

6.  Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.

Authors:  K D Bardhan; P Cherian; A Vaishnavi; R B Jones; M Thompson; P Morris; A Brooks; J D'Silva; K R Gillon; C Wason; J Patterson; J Polak; A Bishop
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 7.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

8.  Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.

Authors:  M J Bruno; E A Rauws; F J Hoek; G N Tytgat
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

Review 9.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing.

Authors:  M Hongo; S Ohara; Y Hirasawa; S Abe; S Asaki; T Toyota
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.